ABSTRACT
Introduction: Adjuvant Online! [AOL] is used extensively by oncologists in Iran to treat patients with breast cancer; however, it has never been validated for use in Iran, and its predictions might not be applicable to Iranian patients. The aim of this study was to evaluate the usefulness of this program in predicting the outcomes of Iranian patients with breast cancer
Patients and methods: 368 patients who were treated between 1997 and 2010 at Jorjani Cancer Center entered the study. Data for each patient, including tumor size, number of positive nodes, tumor grade, ER status, and adjuvant systemic therapy, were entered into the AOL program [version 8.0], and the calculated disease free survival [DFS] was compared with the observed one. Analyses were performed using Cox regression modeling and SPSS 17.0 software, and P values < 0.05 were considered significant
Results: Observed disease free survival [DFS] in our study was 72 months, while the calculated DFS by AOL was 68 months. In all subgroups of AOL, calculated DFS was less than observed DFS except for patients receiving Tamoxifen + Aromatase Inhibitors + Ovarian Ablation hormone therapy, for whom the calculated DFS was 2 percent more than the observed one
Conclusion: AOL underestimated overall survival and disease free survival rates in Iranian patients with breast cancer, which in our opinion was mainly due to the shorter period of follow-up in our study. Although AOL is widely used by Iranian oncologists, we believe that developing an Iranian version of a prediction tool would better predict the prognosis of our patients
ABSTRACT
Cervical cancer is one of the major causes of cancer and death among women aged 40 to 60 in developing countries. There is some difference, however, in the incidence of this cancer in Iranian women compared to women living in western and south-east Asian countries. We aimed at investigating the epidemiologic aspects and treatment results of cervical cancer among Iranian patients. Medical records of patients with cervical cancer who were referred to Mortazavi Radiation Oncology Center [Imam Hossein Hospital] between 2000 and 2004 were evaluated retrospectively. Clinical data such as stage of the disease, type pf chemotherapy, radiation technique and sequence of treatment was recorded. A total of 220 patients with a median age of 55 years [range: 28 to 89] were studied. The majority of them [37.3%] were referred with stage IIB of the disease. Other stages, in order of frequency, were IIA, IIIA and IB. Most of the patients [74%] were treated with two opposed field radiotherapy with a dose of 50 Gy or less [64%]. Disease recurred in 46 patients [21%], 153 patients [74%] received two opposed field radiotherapy and 54 [36%] patients were treated with four fields. On the other hand, 113 patients [55%] did not receive brachytherapy, 36 [18%] only received ovoid brachytherapy and 56 [27%] were treated with ovoid and tandem brachytherapy. Recurrence was more prevalent if the radiotherapy dose was less than 50 Gy and also in patients treated with four-field box technique. The most frequent site of recurrence was pelvic area [71%]. Our report revealed that most of the patients in Iran are diagnosed in advanced stages, a finding that can influence treatment results. Also, using external beam radiotherapy techniques, accessibility to brachytherapy devices and better patient support may improve treatment results